This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
by Zacks Equity Research
BTSG leans on surging Specialty & Infusion and integrated home health branches, but IRA and generic shifts may pressure 2026 margins.
ISRGPositive Net Change WSTNegative Net Change GMEDNo Net Change BTSGNo Net Change
medical medical-devices
Natera Expands Austin Operations With New Sequencing Facility
by Zacks Equity Research
NTRA is expanding in Austin with what it says will be the world's largest sequencing capacity as oncology testing demand keeps surging.
ISRGPositive Net Change WSTNegative Net Change GMEDNo Net Change NTRANegative Net Change
medical medical-devices
Broad-Based MedSurg Growth Likely to Aid MDT's Q4 Performance
by Zacks Equity Research
Medtronic's Q4 results may get a lift from broad MedSurg growth, strong Cardiovascular demand and continued momentum in Diabetes.
LHPositive Net Change MDTNegative Net Change MDPositive Net Change MGNXNegative Net Change
earnings medical medical-devices
4 Stocks With Solid Net Profit Margins to Strengthen Your Portfolio
by Anirudha Bhagat
Here we present four stocks, ATLC, BTSG, ASX and ENVA, with solid net profit margins that can contribute to making a strong portfolio.
ASXNegative Net Change ENVAPositive Net Change ATLCPositive Net Change BTSGNo Net Change
computers fin-tech medical medical-devices pharmaceuticals semiconductor tech-stocks
BrightSpring Leans Into Home Care as IRA Pricing Resets Hit
by Urbi Guha
BTSG is navigating ~$600M of 2026 revenue headwinds while leaning on national scale and home-based coordination to drive margin expansion.
ADUSPositive Net Change OPCHPositive Net Change BTSGNo Net Change
medical medical-devices
Should You Buy BTSG Stock After Raised 2026 Outlook?
by Urbi Guha
BrightSpring raised 2026 targets after a strong Q1 beat, betting home-based scale and tighter execution can drive margin gains despite IRA headwinds.
EHCPositive Net Change OPCHPositive Net Change BTSGNo Net Change
medical medical-devices
Veeva Systems' AI & Vault CRM Strength Signal More Upside Ahead
by Harshit Gupta
VEEV's growing Vault CRM adoption and AI momentum, backed by major pharma wins, reinforce confidence in its long-term growth outlook.
CRMNegative Net Change VEEVNegative Net Change IQVNegative Net Change
medical medical-devices
BTSG Q1 2026 Beat Shows Drivers of Margin Expansion
by Urbi Guha
BrightSpring beat Q1 estimates as revenue rose 25.6% and margins widened; its home-based platform gains traction despite IRA-related revenue pressure.
ADUSPositive Net Change OPCHPositive Net Change BTSGNo Net Change
medical medical-devices
ISRG's Ion Platform: A Major Growth Engine in Lung Cancer Care?
by Indrajit Bandyopadhyay
ISRG's Ion platform saw 39% procedure growth in Q1, with new clinical data strengthening its role in lung cancer diagnosis.
ISRGPositive Net Change STXSNegative Net Change GMEDNo Net Change
medical medical-devices
Can CAH's Surging Other Growth Businesses Become Its Next Profit Engine?
by Indrajit Bandyopadhyay
CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.
CNMDPositive Net Change ALGNNegative Net Change CAHPositive Net Change
medical medical-devices